JMI Laboratories, North Liberty, IA, USA.
Diagn Microbiol Infect Dis. 2013 Mar;75(3):304-7. doi: 10.1016/j.diagmicrobio.2012.11.024. Epub 2013 Jan 26.
Dalbavancin (DAL) is an investigational lipoglycopeptide with a prolonged serum half-life allowing once weekly dosing. DAL potency was assessed in the 2011 SENTRY Antimicrobial Surveillance Program among 1555 isolates sampled from all 9 US Census regions. Monitored Gram-positive cocci included Staphylococcus aureus (SA; 1,036/50.4% MRSA), coagulase-negative staphylococci (CoNS; 115), Enterococcus faecalis (25), E. faecium (31), Streptococcus pyogenes (155), Streptococcus agalactiae (153), and viridans group streptococci (VGS; 40). All susceptibility (S) testing used Clinical and Laboratory Standards Institute reference broth microdilution methods and interpretations. DAL (MIC(50/90), 0.06/0.06 μg/mL) was 8- and 16-fold more active than daptomycin (DAP) and vancomycin (VAN), respectively against SA, with MSSA and MRSA having the same MIC(90) results. CoNS was slightly more DAL-S (MIC(50), ≤0.03μg/mL). The highest staphylococcal DAL MIC was only 0.25 μg/mL. β-Haemolytic streptococci (βHS) and VGS had DAL MIC results ranging from ≤0.03 to 0.25 μg/mL (MIC(90), 0.06-0.12 μg/mL), and only enterococci showed elevated DAL MIC results. VanA phenotype-resistant E. faecalis or E. faecium had DAL MIC values at ≥1 μg/mL; VanB strains were DAL-S (MIC, ≤0.25 μg/mL). All cited DAL quantitative values were consistent with earlier surveillance data (2006-2009), without evidence of MIC creep. In conclusion, year 2011 SENTRY Program data for DAL documents sustained potent activity against SA, CoNS, βHS, VGS, and VAN-S enterococci, which averaged 4- to 32-fold greater than VAN, DAP, or linezolid.
达巴万星（DAL）是一种研究中的糖肽类抗生素，具有延长的血清半衰期，可每周给药一次。2011 年 SENTRY 抗菌监测计划评估了该药的活性，该计划在全美 9 个地区的 1555 株分离株中监测了监测革兰阳性球菌，包括金黄色葡萄球菌（SA；1036/50.4% 为耐甲氧西林金黄色葡萄球菌（MRSA））、凝固酶阴性葡萄球菌（CoNS；115 株）、粪肠球菌（25 株）、屎肠球菌（31 株）、化脓性链球菌（155 株）、无乳链球菌（153 株）和草绿色链球菌（VGS；40 株）。所有药敏（S）检测均采用临床和实验室标准协会（CLSI）参考肉汤微量稀释法及判读标准。达巴万星（DAL）（MIC（50/90），0.06/0.06μg/mL）对 SA 的活性分别是达托霉素（DAP）和万古霉素（VAN）的 8 倍和 16 倍，MSSA 和 MRSA 的 MIC（90）结果相同。CoNS 对达巴万星（DAL）更为敏感（MIC（50），≤0.03μg/mL）。SA 的最高达巴万星 MIC 仅为 0.25μg/mL。β-溶血性链球菌（βHS）和草绿色链球菌的达巴万星 MIC 结果范围为≤0.03-0.25μg/mL（MIC（90），0.06-0.12μg/mL），只有肠球菌对达巴万星的 MIC 结果升高。VanA 表型耐药的粪肠球菌或屎肠球菌的达巴万星 MIC 值≥1μg/mL；VanB 株对达巴万星敏感（MIC，≤0.25μg/mL）。所有引用的达巴万星定量值与早期监测数据（2006-2009 年）一致，未发现 MIC 上升的证据。总之，2011 年 SENTRY 监测计划的数据显示，达巴万星对 SA、CoNS、βHS、VGS 和 VanB 表型肠球菌保持着强大的活性，其活性平均比万古霉素、达托霉素或利奈唑胺高 4-32 倍。
